1. Home
  2. TBPH vs ATGL Comparison

TBPH vs ATGL Comparison

Compare TBPH & ATGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • ATGL
  • Stock Information
  • Founded
  • TBPH 2013
  • ATGL 2017
  • Country
  • TBPH United States
  • ATGL Hong Kong
  • Employees
  • TBPH N/A
  • ATGL N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • ATGL
  • Sector
  • TBPH Health Care
  • ATGL
  • Exchange
  • TBPH Nasdaq
  • ATGL Nasdaq
  • Market Cap
  • TBPH 464.5M
  • ATGL 409.9M
  • IPO Year
  • TBPH N/A
  • ATGL 2023
  • Fundamental
  • Price
  • TBPH $8.91
  • ATGL $24.52
  • Analyst Decision
  • TBPH Buy
  • ATGL
  • Analyst Count
  • TBPH 3
  • ATGL 0
  • Target Price
  • TBPH $11.33
  • ATGL N/A
  • AVG Volume (30 Days)
  • TBPH 268.3K
  • ATGL 11.3K
  • Earning Date
  • TBPH 05-08-2025
  • ATGL 12-31-2024
  • Dividend Yield
  • TBPH N/A
  • ATGL N/A
  • EPS Growth
  • TBPH N/A
  • ATGL N/A
  • EPS
  • TBPH N/A
  • ATGL N/A
  • Revenue
  • TBPH $65,266,000.00
  • ATGL $1,590,148.00
  • Revenue This Year
  • TBPH $51.09
  • ATGL N/A
  • Revenue Next Year
  • TBPH N/A
  • ATGL N/A
  • P/E Ratio
  • TBPH N/A
  • ATGL N/A
  • Revenue Growth
  • TBPH 6.11
  • ATGL 42.17
  • 52 Week Low
  • TBPH $7.44
  • ATGL $1.15
  • 52 Week High
  • TBPH $10.90
  • ATGL $57.32
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 40.95
  • ATGL 42.61
  • Support Level
  • TBPH $8.69
  • ATGL $25.57
  • Resistance Level
  • TBPH $10.55
  • ATGL $26.01
  • Average True Range (ATR)
  • TBPH 0.38
  • ATGL 1.52
  • MACD
  • TBPH -0.12
  • ATGL -0.33
  • Stochastic Oscillator
  • TBPH 12.06
  • ATGL 27.23

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About ATGL Alpha Technology Group Limited

Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.

Share on Social Networks: